Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Chronic Spontaneous Urticaria (INCEPTION)
NCT04833855Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of tezepelumab in chronic spontaneous urticaria (CSU), sponsored by Amgen. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04833855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833855.